WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Barclays PLC (NYSE: BCS) resulting from allegations that Barclays may have issued materially misleading business information to the investing public.
TAMPA, Fla., June 4, 2026 /PRNewswire/ -- The Tampa Museum of Art today announced a transformative gift from longtime Museum leaders and supporters Maureen...
Delivering the Ultimate AAA Gameplay Experience, Display Leader Introduces Three New QD-Mini LED Gaming MonitorsIRVINE, Calif., June 4, 2026 /PRNewswire/ -- TCL®, one of the world's...
Data center industry veteran to oversee development, product strategy, and service delivery as Flexential accelerates nationwide growthDENVER, June 4, 2026 /PRNewswire/ -- Flexential, a...
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
Chinese model targets local issues, improves livelihoods in remote Laos settlementLUANG PRABANG, Laos, June 4, 2026 /PRNewswire/ -- A report from Chinadaily.com.cnTo mark the...
LONDON, June 4, 2026 /PRNewswire/ -- New research from Pearson (FTSE: PSON.L), the world's lifelong learning company, suggests that UK teachers' confidence in using AI...
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.
GRIMSBY, Ontario, June 03, 2026 (GLOBE NEWSWIRE) -- Andrew Peller Limited (ADW.A / ADW.B) will issue its financial results for the three and 12 months ended March 31, 2026, after close of market on Tuesday, June 16, 2026. Management will host a conference call to discuss the financial results on Wednesday, June 17, 2026, at 10:00 a.m. (ET), followed by a question-and-answer period.